论文部分内容阅读
目的:观察乳酸乳杆菌对溃疡性结肠炎的辅助治疗效果及相关机制。方法:研究对象为121名中度以上的溃疡性结肠炎患者,随机分为对照组和观察组,对照组是常规治疗;而观察组是在常规治疗的基础上,服用乳酸菌胶囊(主要含短乳酸乳杆菌),每天3次,服药时间为1年。观察试验开始和治疗1年后2组患者的结肠镜黏膜分数、灌洗液中髓过氧化物酶的含量,同时检测2组患者治疗前后粪便中的细菌数。结果:在经过1年治疗后,通过结肠镜检验,发现观察组溃疡性结肠炎患者的临床状况有明显改善,同时观察组患者中MPO(myeloperoxidase)、粪便中的肠杆菌数量和p H值均显著降低。结论:使用活性乳酸乳杆菌能明显改善溃疡性结肠炎患者的临床状况,可以作为溃疡性结肠炎患者的长期辅助治疗措施。
Objective: To observe the effects of lactobacillus lactis on ulcerative colitis and related mechanisms. Methods: The subjects were 121 patients with moderate-to-moderate ulcerative colitis who were randomly divided into control group and observation group. The control group was treated routinely. The observation group was treated with lactic acid bacteria capsule Lactobacillus lactis), 3 times a day, taking a time of 1 year. The colon mucosal score, the amount of myeloperoxidase in the lavage fluid, and the number of bacteria in the feces of the two groups before and after treatment were observed at the beginning of the experiment and one year after the treatment. RESULTS: After one year of treatment, colonoscopy revealed significant improvement in the clinical status of patients with ulcerative colitis in the observation group, while MPO (myeloperoxidase) in the observation group, the number of Enterobacteriaceae and the p H value in the stool Significantly lower. Conclusion: The use of active Lactobacillus lactis can significantly improve the clinical status of patients with ulcerative colitis, which can be used as long-term adjuvant therapy in patients with ulcerative colitis.